Clinical Trials Browser

Phase NA × regorafenib × Gastrointestinal × Clear all

NCT07115550 2025-08-11

A Single-center, Single-arm, Phase II Clinical Study of Iparomlimab and Tuvonralimab Injection Combined With Regorafenib in the Treatment of Advanced Second-line or Above Hepatocellular Carcinoma

Phase NA Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT06456515 2025-02-17

Regorafenib and Sintilimab in Combination with Electroacupuncture in MSS CRC

Phase NA Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT02175095 2024-10-04

[18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib

Phase NA Completed

68 enrolled 15 charts

Gastrointestinal

Colorectal Neoplasms

NCT05818267 2023-07-14

Efficacy and Safety of Regorafenib Maintenance Therapy in Patients With Metastatic Colorectal Cancer (mCRC)

Phase NA Unknown

Gastrointestinal

Colorectal Neoplasms

NCT05233358 2022-02-10

HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure

Phase NA Unknown

Gastrointestinal

Carcinoma, Hepatocellular

NCT01996969 2019-02-22

Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal Cancer

Phase NA Completed

Gastrointestinal

Colorectal Neoplasms

NCT03698253 2018-10-05

Metastatic Colorectal Cancer Treated With Regorafenib and FOLFIRI

Phase NA Completed

Gastrointestinal

Colorectal Neoplasms